BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah SJ, Voors AA, McMurray JJV, Kitzman DW, Viethen T, Bomfim Wirtz A, Huang E, Pap AF, Solomon SD. Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA 2019;321:2101-12. [PMID: 31162568 DOI: 10.1001/jama.2019.6717] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Vaz-salvador P, Adão R, Vasconcelos I, Leite-moreira AF, Brás-silva C. Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update. Cardiovasc Drugs Ther. [DOI: 10.1007/s10557-021-07306-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Vaikunth SS, Lui GK. Heart failure with reduced and preserved ejection fraction in adult congenital heart disease. Heart Fail Rev 2020;25:569-81. [PMID: 31873841 DOI: 10.1007/s10741-019-09904-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Vincenzi F, Pasquini S, Battistello E, Merighi S, Gessi S, Borea PA, Varani K. A1 Adenosine Receptor Partial Agonists and Allosteric Modulators: Advancing Toward the Clinic? Front Pharmacol 2020;11:625134. [PMID: 33362567 DOI: 10.3389/fphar.2020.625134] [Reference Citation Analysis]
4 IJzerman AP, Jacobson KA, Müller CE, Cronstein BN, Cunha RA. International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update. Pharmacol Rev 2022;74:340-72. [PMID: 35302044 DOI: 10.1124/pharmrev.121.000445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
5 Pagel PS, Tawil JN, Boettcher BT, Izquierdo DA, Lazicki TJ, Crystal GJ, Freed JK. Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. J Cardiothorac Vasc Anesth 2021;35:1839-59. [PMID: 32747202 DOI: 10.1053/j.jvca.2020.07.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Md MA, Parrott CF, Ph D MJH, Ph D PHB, Md FY, Md BU. Skeletal muscle abnormalities in heart failure with preserved ejection fraction. Heart Fail Rev 2022. [PMID: 35353269 DOI: 10.1007/s10741-022-10219-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bisaccia G, Ricci F, Gallina S, Di Baldassarre A, Ghinassi B. Mitochondrial Dysfunction and Heart Disease: Critical Appraisal of an Overlooked Association. Int J Mol Sci 2021;22:E614. [PMID: 33435429 DOI: 10.3390/ijms22020614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Del Buono MG, Iannaccone G, Scacciavillani R, Carbone S, Camilli M, Niccoli G, Borlaug BA, Lavie CJ, Arena R, Crea F, Abbate A. Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. Progress in Cardiovascular Diseases 2020;63:570-84. [DOI: 10.1016/j.pcad.2020.04.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
9 Wachter R, Shah SJ, Cowie MR, Szecsödy P, Shi V, Ibram G, Zhao Z, Gong J, Klebs S, Pieske B. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Fail 2020;7:856-64. [PMID: 32297449 DOI: 10.1002/ehf2.12694] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
10 Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020;17:559-73. [DOI: 10.1038/s41569-020-0363-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 26.0] [Reference Citation Analysis]
11 Graziani F, Lillo R, Crea F. Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction. Front Cardiovasc Med 2021;8:678530. [PMID: 33969025 DOI: 10.3389/fcvm.2021.678530] [Reference Citation Analysis]
12 Shah RV, Schoenike MW, Armengol de la Hoz MÁ, Cunningham TF, Blodgett JB, Tanguay M, Sbarbaro JA, Nayor M, Rouvina J, Kowal A, Houstis N, Baggish AL, Ho JE, Hardin C, Malhotra R, Larson MG, Vasan RS, Lewis GD. Metabolic Cost of Exercise Initiation in Patients With Heart Failure With Preserved Ejection Fraction vs Community-Dwelling Adults. JAMA Cardiol 2021;6:653-60. [PMID: 33729454 DOI: 10.1001/jamacardio.2021.0292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Amelia T, van Veldhoven JPD, Falsini M, Liu R, Heitman LH, van Westen GJP, Segala E, Verdon G, Cheng RKY, Cooke RM, van der Es D, IJzerman AP. Crystal Structure and Subsequent Ligand Design of a Nonriboside Partial Agonist Bound to the Adenosine A2A Receptor. J Med Chem 2021;64:3827-42. [PMID: 33764785 DOI: 10.1021/acs.jmedchem.0c01856] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Aronow WS, Lloji A, Sreenivasan J, Novograd J, Pan S, Lanier GM. Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials. Expert Opin Investig Drugs 2022. [PMID: 35443138 DOI: 10.1080/13543784.2022.2069009] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Shah SJ, Cowie MR, Wachter R, Szecsödy P, Shi V, Ibram G, Hu M, Zhao Z, Gong J, Pieske B. Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction. Eur J Heart Fail 2021. [PMID: 34170062 DOI: 10.1002/ejhf.2277] [Reference Citation Analysis]
16 Davila A, Tian Y, Czikora I, Li J, Su H, Huo Y, Patel V, Robinson V, Kapuku G, Weintraub N, Bagi Z. Adenosine Kinase Inhibition Augments Conducted Vasodilation and Prevents Left Ventricle Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 2019;12:e005762. [PMID: 31525084 DOI: 10.1161/CIRCHEARTFAILURE.118.005762] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
17 Rueda P, Merlin J, Chimenti S, Feletou M, Paysant J, White PJ, Christopoulos A, Sexton PM, Summers RJ, Charman WN, May LT, Langmead CJ. Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure. Front Pharmacol 2021;12:628060. [PMID: 33776771 DOI: 10.3389/fphar.2021.628060] [Reference Citation Analysis]
18 Aimo A, Senni M, Barison A, Panichella G, Passino C, Bayes-Genis A, Emdin M. Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. Heart Fail Rev 2022. [PMID: 35488030 DOI: 10.1007/s10741-022-10228-8] [Reference Citation Analysis]
19 Correale M, Tricarico L, Fortunato M, Mazzeo P, Nodari S, Di Biase M, Brunetti ND. New Targets in Heart Failure Drug Therapy. Front Cardiovasc Med 2021;8:665797. [PMID: 34026873 DOI: 10.3389/fcvm.2021.665797] [Reference Citation Analysis]
20 Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, Shi V, Zhao Z, Cowie MR; PARALLAX Investigators and Committee members. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA 2021;326:1919-29. [PMID: 34783839 DOI: 10.1001/jama.2021.18463] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
21 Dal Ben D, Lambertucci C, Buccioni M, Martí Navia A, Marucci G, Spinaci A, Volpini R. Non-Nucleoside Agonists of the Adenosine Receptors: An Overview. Pharmaceuticals (Basel) 2019;12:E150. [PMID: 31597388 DOI: 10.3390/ph12040150] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
22 Jiang Y, Lin J, Zheng H, Zhu P. The Role of Purinergic Signaling in Heart Transplantation. Front Immunol 2022;13:826943. [DOI: 10.3389/fimmu.2022.826943] [Reference Citation Analysis]
23 Azhar G, Wei JY, Schutzler SE, Coker K, Gibson RV, Kirby MF, Ferrando AA, Wolfe RR. Daily Consumption of a Specially Formulated Essential Amino Acid-Based Dietary Supplement Improves Physical Performance in Older Adults With Low Physical Functioning. J Gerontol A Biol Sci Med Sci 2021;76:1184-91. [PMID: 33475727 DOI: 10.1093/gerona/glab019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 McNeill SM, Baltos JA, White PJ, May LT. Biased agonism at adenosine receptors. Cell Signal 2021;82:109954. [PMID: 33610717 DOI: 10.1016/j.cellsig.2021.109954] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Campos-Martins A, Bragança B, Correia-de-Sá P, Fontes-Sousa AP. Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction. Front Pharmacol 2021;12:724320. [PMID: 34489711 DOI: 10.3389/fphar.2021.724320] [Reference Citation Analysis]